Prognostic significance of combined PD-L1 expression in malignant and infiltrating cells in hepatocellular carcinoma treated with atezolizumab and bevacizumab DOI Creative Commons
Jae Jun Lee, Jae-Sung Yoo, Ji Hoon Kim

и другие.

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Дек. 10, 2024

Background Programmed death-ligand 1 (PD-L1) expression is abundant not only in malignant cells but also infiltrating within the tumor microenvironment (TME) of hepatocellular carcinoma (HCC). This study explored association between PD-L1 TME and outcomes HCC patients treated with atezolizumab plus bevacizumab (AB), emphasizing implications both tumor-infiltrating cells. Methods included 72 who underwent percutaneous core needle liver biopsy before AB treatment September 2020 December 2023. on tissues was assessed using combined positive score (CPS) cutoff values 10, utilizing antibody clone 22C3 (Dako). Results The distribution CPS 24 <1, 33 1–10, 15 ≥10. Significant differences overall survival (OS) were observed across three groups, ≥10 showing highest rates (p = 0.010). Patients had better OS than those <10 (median 14.8 vs. 8.3 months, P 0.046), ≥1 <1 (P 0.021). For progression-free (mPFS), group median PFS 11.0 months among groups 0.044). Objective response (ORR) higher 1-10 (53.3%, 27.3%, 16.7%, respectively; .047). Multivariate analysis identified that associated favorable regarding (hazard ratio [HR] 0.283, .027 HR 0.303, .006, respectively). Conclusions Combined can be a promising biomarker for prognosis AB.

Язык: Английский

Prognostic significance of combined PD-L1 expression in malignant and infiltrating cells in hepatocellular carcinoma treated with atezolizumab and bevacizumab DOI Creative Commons
Jae Jun Lee, Jae-Sung Yoo, Ji Hoon Kim

и другие.

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Дек. 10, 2024

Background Programmed death-ligand 1 (PD-L1) expression is abundant not only in malignant cells but also infiltrating within the tumor microenvironment (TME) of hepatocellular carcinoma (HCC). This study explored association between PD-L1 TME and outcomes HCC patients treated with atezolizumab plus bevacizumab (AB), emphasizing implications both tumor-infiltrating cells. Methods included 72 who underwent percutaneous core needle liver biopsy before AB treatment September 2020 December 2023. on tissues was assessed using combined positive score (CPS) cutoff values 10, utilizing antibody clone 22C3 (Dako). Results The distribution CPS 24 <1, 33 1–10, 15 ≥10. Significant differences overall survival (OS) were observed across three groups, ≥10 showing highest rates (p = 0.010). Patients had better OS than those <10 (median 14.8 vs. 8.3 months, P 0.046), ≥1 <1 (P 0.021). For progression-free (mPFS), group median PFS 11.0 months among groups 0.044). Objective response (ORR) higher 1-10 (53.3%, 27.3%, 16.7%, respectively; .047). Multivariate analysis identified that associated favorable regarding (hazard ratio [HR] 0.283, .027 HR 0.303, .006, respectively). Conclusions Combined can be a promising biomarker for prognosis AB.

Язык: Английский

Процитировано

0